Relative importance of blood-based biomarkers for Alzheimer’s disease-specific neurodegeneration and cognitive decline

Journal of Prevention of Alzheimer's Disease · Published 2026-07-11 · DOI 10.1016/j.tjpad.2026.100644

Free full text

Authors (6)

Keun You Kim, Hyunsun Ham, Eun Jin Yoon, Eosu Kim, Yu Kyeong Kim, Jun-Young Lee

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kim, K., Ham, H., Yoon, E., et al. (2026). Relative importance of blood-based biomarkers for Alzheimer’s disease-specific neurodegeneration and cognitive decline. Journal of Prevention of Alzheimer's Disease. https://doi.org/10.1016/j.tjpad.2026.100644

Related articles

• Reductions in neuropsychiatric symptoms after lecanemab treatment and their associations with imaging markers of β-amyloid clearance · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Combined effect of anxiety disorder and insomnia on the risk of incident ADRD diagnosis · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Sex differences in subjective cognition among middle-aged and older Hispanic/Latino adults: Findings from the HCHS/SOL and SOL-INCA · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Plasma brain-derived p-Tau217 outperforms other p-Tau species in detecting abnormal brain amyloid in an Asian cohort of older people with cerebrovascular disease burden · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Suboptimal adherence to brain health recommendations in patients pursuing anti-amyloid antibody therapy for Alzheimer’s disease: Report from the Brain Health Vital Signs project · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Depressive symptoms as a risk factor or prodrome of dementia: multi-state cognitive transitions modified by age and polygenic risk · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Tailored implementation of multidomain intervention to prevent cognitive impairment in community-dwelling older adults (Timi-Cog): A study protocol for a hybrid type 2 trial effectiveness-implementation study · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Top five Alzheimer Disease trial eligibility criteria favor men compared to women in a clinic-based cohort · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Associations of plasma biomarkers with age in the presenilin-1 E280A autosomal dominant Alzheimer's disease kindred · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal